ClinicalTrials.gg
CompletedNCT03376763MAESTROUpdated Dec 17, 2021

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

A Phase 4 interventional study of Abilify maintena in Schizophrenia, Antipsychotics and Long-Acting Injection, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 27 sites in Korea, Republic of. Open to participants aged 19 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Non-randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
48th of 125
201 · median 130
Started
2017
with 5 others
Phase 4
56 of 126
2 open now
Registered
108th of 126
by date
Lead sponsor
3 of 126
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 48th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2017, is one of 56 in phase 4, and was the 108th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

Interventional, multicenter, open-label, 20 weeks study

  • To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
  • To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena
Read the detailed description

We would like to evaluate the efficacy and safety when switching to Abilify Maintena according to the approved indication of Abilify Maintena, for subjects who are taking oral antipsychotic drugs. It is expected that this will serve as a basis for suggesting a successful switching guideline from oral antipsychotics to Abilify Maintena, which can be applicable in clinical practice.

03

Conditions studied

  • Schizophrenia
  • Antipsychotics
  • Long-Acting Injection
  • LAI
  • Aripiprazole

Browse trials for

Keywords

  • aripiprazole
  • Long-Acting Injection
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who voluntarily consented to participating in the clinical trial.
  2. Male and female legally aged ≥19 and \< 65 years.
  3. Subjects who were diagnosed of schizophrenia as defined by DSM diagnostic criteria, and were diagnosed of schizophrenia for at least for 2 years prior to screening.
  4. Subjects with all of the following schizophrenia clinical features:

    A. Outpatient subjects, with no hospitalization for worsening of schizophrenia within 3 months prior to screening.

    B. Subjects who have no more than a moderate rating on the PANSS total score≤80 C. 4 individual PANSS items, which are concerning to psychotic symptom (P2. conceptual disorganization, P3. hallucinatory behavior, P6. suspiciousness/persecution, G9. unusual thought content), score≤4.

    D. CGI-S score ≤4 (moderately ill).

  5. Subjects who take atypical antipsychotic drugs with the therapeutic effective dose (as specified in each label) for schizophrenia treatment, and should be maintained on the type and dose of the current antipsychotic drugs (including both typical and atypical antipsychotic drugs) for at least 4 weeks prior to the screening.
  6. Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to Abilify Maintena on the investigator's judgement.
  7. Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures as per the investigator's judgment.

Exclusion criteria

Exclusion criteria

  1. Subject who showed medically significant adverse events or intolerance with aripiprazole during screening period or as prior experiences.
  2. Subjects with a current DSM diagnostic criteria-based diagnosis other than schizophrenia, including Schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, neurocognitive disorder due to Alzheimer's or similar diseases, amnesia, borderline, paranoid, histrionic, schizotypal, schizoid, antisocial or other cognitive or personality disorders.
  3. Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.
  4. Subjects who have been treated with clozapine, electroconvulsive therapy (ECT) or other long-acting injectable antipsychotic drugs within 3 months prior to the screening.
  5. Subjects who have been treated more than 2 oral antipsychotic drugs (including both typical and atypical antipsychotic drugs) with the minimum therapeutic effective dose (as specified in each label) for schizophrenia treatment at screening.

    (e.g. Aripiprazole≥10 mg/day, Olanzapine≥10 mg/day, Risperidone≥2 mg/day, Quetiapine ≥150 mg/day)

  6. Subjects who have been treated with oral antipsychotic drugs (including both typical and atypical antipsychotic drugs) exceeding maximum maintenance dose (as specified in each label) at screening.

    (e.g. Aripiprazole>30 mg/day, Olanzapine>20 mg/day, Risperidone > 6 mg/day, Quetiapine > 750 mg/day)

  7. Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
  8. Subjects had a history of seizures, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose them to undue risk or interfere with study assessments.
  9. Significant history of drug abuse disorder (excluding caffeine and nicotine, including alcohol, as defined in substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening.
  10. Subjects who participated in another interventional clinical trial within 30 days prior to screening.
  11. Pregnant or lactating women, or women of who are not willing to or not able to use methods (sexual abstinence; oral, implanted or injection hormone contraceptive methods; intrauterine device or condom; barrier contraceptive methods such as diaphragm and spermicide), accepted to avoid pregnancy until the end of the clinical trial.
  12. Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Group 1

    Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena

    Drug: Abilify maintena

  • Experimental
    Group 2

    Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena

    Drug: Abilify maintena

Interventions

  • Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)

    Also known as: long-acting injectable aripiprazole

06

What researchers measure

Primary outcomes

  1. PANSS total score

    Change in PANSS total score from baseline to Week 16

    Time frame: 16 weeks

Secondary outcomes

  1. CGI-S

    Change in CGI-S (severity) from baseline to Week 16

    Time frame: 16 weeks

  2. CGI-I

    Mean CGI-I (improvement) score at Week 16

    Time frame: 16 weeks

  3. PANSS positive and negative subscale score

    Change in PANSS positive and negative subscale score from baseline to Week 16

    Time frame: 16 weeks

  4. IAQ score

    Mean IAQ score at Week 16

    Time frame: 16 weeks

Other outcomes

  1. study discontinuation rates

    Comparison the study discontinuation rates between Group 1 and Group 2

    Time frame: 16 weeks

  2. study discontinuation rates

    Comparison the study discontinuation rates in Group 2 depending on the other oral atypical antipsychotics

    Time frame: 16 weeks

  3. proportion of subjects who have more than 20% increased rating on the PANSS total score

    Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 between Group 1and Group 2

    Time frame: 16 weeks

  4. proportion of subjects who have more than 20% increased rating on the PANSS total score

    Comparison the proportion of subjects who have more than 20% increased rating on the PANSS total score from baseline to Week 16 in Group 2 depending on the other oral atypical antipsychotics

    Time frame: 16 weeks

07

Study locations

27 sites
  • Konkuk University Chungju Hospital
    Chungju, Chungcheongbuk-do 27376, Korea, Republic of
  • Gongju National Hospital
    Gongju, Chungcheongnam-do 32601, Korea, Republic of
  • Hanyang University Guri Hospital
    Guri-si, Gyeonggi-do, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si,, Gyeonggi-do, Korea, Republic of
  • Cha Bundang Medical Center
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • The Catholic University of Korea Uijeongbu ST. Mary'S Hospital
    Uijeongbu Si, Gyeonggi-do, Korea, Republic of
  • Yong-In Mental Hospital
    Yongin-si, Gyeonggi-do 17089, Korea, Republic of
  • Jeju National University Hospital
    Jeju, Jeju-do 63241, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, Jeollabuk-do, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
  • Yeungnam University Medical Center
    Daegu, Korea, Republic of
  • Eulji University Hospital
    Daejeon, 35233, Korea, Republic of
  • Konyang University Hospital
    Daejeon, 35365, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • International St. Mary's Hospital
    Incheon, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Pusan, Korea, Republic of
  • Pusan National University Yangsan Hospital
    Pusan, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Eulji General Hospital
    Seoul, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, Korea, Republic of
  • Seoul National University Hosipital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Aripiprazole Investigator Brochure, Version No. 20, 16 Aug 2016
  • Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993 Feb;50(2):85-94. doi: 10.1001/archpsyc.1993.01820140007001. PubMed 8427558 ↗
  • Hong Kyu Ihm et al. Factors Related to Medication Adherence in Outpatients with Schizophrenia under More Than 5 Years of Treatment. J Korean Neuropsychiatr Assoc 2016; 55(4):397-406
  • Hyun-Ku Kang, et al. Safety and Effectiveness of Long Acting Injectable Antipsychotic Paliperidone Palmitate Treatment in Schizophrenics: A 24-Week Open-Label Study. Korean J Biol Psychiatry 2013;20:111-117
  • Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995 Mar;52(3):173-88. doi: 10.1001/archpsyc.1995.03950150005001. No abstract available. PubMed 7872841 ↗
  • Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001 Nov;158(11):1835-42. doi: 10.1176/appi.ajp.158.11.1835. PubMed 11691689 ↗
  • Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530. PubMed 22697189 ↗
  • Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015 Oct;168(1-2):498-504. doi: 10.1016/j.schres.2015.07.007. Epub 2015 Jul 29. PubMed 26232241 ↗
  • Seockhoon Chung, Chang Yoon Kim. et al. Effectiveness and Tolerability of Long-Acting Risperidone:A 12 Weeks, Multi-center Switching Study from Oral Antipsychotics. Korean J Psychopharmacol 16/2:109-120, 2005
  • Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014 Aug;205(2):135-44. doi: 10.1192/bjp.bp.113.134213. Epub 2014 Jun 12. PubMed 24925984 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2021, 47 months.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 18, 2017
StartActual
Nov 21, 2017
Primary completionActual
Nov 19, 2021
CompletionActual
Nov 19, 2021
Last update
Dec 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03376763
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Nov 21, 2017
Primary completion
Nov 19, 2021
Completion
Nov 19, 2021
Last update
Dec 17, 2021

Study contacts

Jun Soo Kwon, Dr.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion